Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Otorhinolaryngol Ital ; 43(6): 365-374, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37814980

ABSTRACT

Objectives: Malignant minor salivary glands carcinomas (MiSGC) of the larynx and trachea are rare tumours and published evidence is sparse. We conducted a systematic review to describe shareable treatment strategies and oncological outcomes of these neoplastic entities. Methods: Full text English manuscripts published from January 1st 2000 to December 14th 2022 were included. Data on demographics, treatments and outcomes were collected. A pooled analysis of 5-year overall survival (OS) was performed. Results: Seventeen articles and 365 patients met the inclusion criteria. The most common subsites involved were subglottic and distal trachea. Adenoid cystic carcinoma was, by far, the most frequent histotype. The first-choice treatment strategy was surgery (86.8%), while adjuvant treatments were delivered in 57.4% of patients. Only 12.9% were treated with definitive radiotherapy with/without chemotherapy. The mean follow-up was 68.3 months. One hundred nine (34.9%) deaths were recorded and 62.4% were cancer-related. Five-year OS ranged from 20% to 100% and, at pooled analysis, it was 83% (range, 78-87%). Conclusions: In case of MiSGC of the larynx and trachea, surgery remains the mainstay of treatment. Adjuvant treatments are frequently delivered. Survival estimates are good overall, but highly heterogeneous.


Subject(s)
Carcinoma, Adenoid Cystic , Larynx , Salivary Gland Neoplasms , Humans , Trachea , Salivary Gland Neoplasms/therapy , Salivary Gland Neoplasms/pathology , Larynx/pathology , Carcinoma, Adenoid Cystic/pathology , Carcinoma, Adenoid Cystic/therapy , Retrospective Studies , Treatment Outcome , Salivary Glands, Minor/pathology
2.
Acta Otorhinolaryngol Ital ; 43(5): 310-316, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37519139

ABSTRACT

Objectives: Head and neck adenosquamous cell carcinoma (HN-ASCC) is a rare, aggressive neoplasm, with limited data reported in the literature. The aim of this study was to assess tumour behaviour and prognostic factors impacting overall survival (OS) in a retrospective, single institution series. Methods: A retrospective study on patients affected by HN-ASCC who were treated surgically between 2002 and 2019 at the Department of Otorhinolaryngology - Head and Neck Surgery of the University of Brescia was conducted. Demographics, clinical data, OS, and relative prognostic factors were analysed. Results: The study included 32 patients, with a median age of 66 years, mostly males (84.4%) and untreated (68.8%). Adjuvant treatments followed surgery in 28.1% of patients. Compared to conventional SCC, ASCC showed a higher proportion of cases arising in the larynx (40.6%); no difference was found in other features. Advanced (pT3-4) local stage at presentation (p = 0.023), perineural invasion (PNI, p = 0.01), and positive margins (p = 0.007) were independent negative prognostic factors for OS. Conclusions: HN-ASCC is a rare, aggressive cancer, most frequently arising in the larynx of elderly males, usually diagnosed in an advanced local stage. OS is generally poor, affected by local advanced stage, PNI, and positive resection margins.

3.
Head Neck ; 45(6): 1486-1496, 2023 06.
Article in English | MEDLINE | ID: mdl-36995898

ABSTRACT

BACKGROUND: Aim of this study is to investigate the prevalence of cervical nodal metastasis at presentation and as disease relapse in primary, treatment-naive olfactory neuroblastoma (ONB), and to review treatment modalities, risk factors for regional failure and survival outcomes according to nodal status. METHODS: A systematic review and proportion meta-analysis were conducted following PRISMA guidelines based on PubMed, Web of Science, and Scopus. RESULTS: Eighteen articles were examined. The pooled proportion of patients with nodal metastasis at presentation (11.5%) was comparable to that of cN0 patients not receiving elective neck treatment developing nodal metastasis during follow-up (12.3%). Of the latter, most were Kadish stage C tumors (85.5%). CONCLUSIONS: Cervical involvement is common both at presentation and during follow-up of cN0 ONB. The highest risk of developing late nodal metastasis is seen in cN0 patients with Kadish stage C tumors not receiving elective neck treatment. Elective cN0 neck treatment should be encouraged in selected patients to increase regional control.


Subject(s)
Carcinoma , Esthesioneuroblastoma, Olfactory , Nose Neoplasms , Humans , Lymphatic Metastasis/pathology , Esthesioneuroblastoma, Olfactory/epidemiology , Esthesioneuroblastoma, Olfactory/therapy , Esthesioneuroblastoma, Olfactory/pathology , Prevalence , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/pathology , Carcinoma/pathology , Neck Dissection , Nose Neoplasms/epidemiology , Nose Neoplasms/therapy , Nasal Cavity/pathology , Retrospective Studies , Lymph Nodes/pathology , Neoplasm Staging
4.
Head Neck ; 44(8): 1857-1870, 2022 08.
Article in English | MEDLINE | ID: mdl-35652409

ABSTRACT

BACKGROUND: Evidence on survival and major prognosticators after salvage surgery in recurrent sinonasal cancers (SNC) is limited. METHODS: A retrospective, single-center study of recurrent SNC treated with salvage surgery between 1997 and 2019 was conducted. Univariate and multivariable analyses were performed to define a prognostic score for overall survival (OS). RESULTS: One hundred and eighteen patients were included. Recurrent SNC originated mostly in the naso-ethmoidal box (67.8%) and were mainly epithelial (76.2%), high-grade (49.2%), and locally advanced (rpT4, 60.1%) malignancies. Negative margins were achieved in 56.6% of cases. Two- and 5-year OS were 71.7% and 56%, respectively. The prognostic model included treatment modality for primary tumor, histology, rpT class, margin status, perineural invasion, and adjuvant radiotherapy and stratified patients into three prognostic groups (5-year OS: 84.4%, 44.9%, and 0%, respectively). CONCLUSIONS: Treatment of recurrent SNC can result in good long-term survival estimates with limited morbidity. Our score can provide excellent prognostic stratification.


Subject(s)
Neoplasm Recurrence, Local , Paranasal Sinus Neoplasms , Humans , Neoplasm Recurrence, Local/pathology , Paranasal Sinus Neoplasms/pathology , Prognosis , Retrospective Studies , Salvage Therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...